Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
AIMC Altra Industrial Motion Corp
TRST TrustCo Bank Corp N Y
VNE Veoneer Inc
ZS Zscaler Inc
SSTK Shutterstock Inc
SUI Sun Communities Inc
SLB Schlumberger NV
NWHUF NorthWest Healthcare Properties REIT
BBI Brickell Biotech Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Closing Price
$109.14
Day's Change
0.38 (0.35%)
Bid
--
Ask
--
B/A Size
--
Day's High
109.22
Day's Low
108.31
Volume
(Below Average)
Volume:
4,614,352

10-day average volume:
5,733,270
4,614,352

Display:

Providers:

UpdateCancel
6 providers
October 19, 2021
Is This The Most Exciting Medical Breakthrough Of The Decade

According to Google's Health boss David Feinberg... over one billion people a day search Google for health concerns. But, what if, instead... they could "consult" a phone app with the power of hundreds of doctors? Mentioned in today's commentary...(PR Newswire)

October 11, 2021
Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month. For the month of October and into 2022, Allergan Aesthetics , The...(PR Newswire)

October 07, 2021
AbbVie's Upadacitinib (RINVOQ(R)) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis

AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis (nr-axSpA), showing upadacitinib (RINVOQ(R); 15 mg, once daily) met...(PR Newswire)

October 05, 2021
AbbVie to Host Third-Quarter 2021 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through...(PR Newswire)

October 02, 2021
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021

AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI(R)) in Crohn's disease, upadacitinib (RINVOQ(R)) in ulcerative colitis and HUMIRA(R) (adalimumab) in inflammatory bowel disease (IBD) will be presented as live...(PR Newswire)

September 30, 2021
AbbVie Presents New Analyses Evaluating RINVOQ(R) (upadacitinib) in Atopic Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress

AbbVie (NYSE: ABBV) today announced new analyses from the Phase 3 RINVOQ(R) (upadacitinib) atopic dermatitis clinical trial program to be presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress. One analysis...(PR Newswire)

September 28, 2021
FDA Approves QULIPTA(TM) (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA(TM) (atogepant) for the preventive treatment of episodic migraine in adults.1 QULIPTA is the first and only oral calcitonin gene-related peptide...(PR Newswire)

September 27, 2021
Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals

From texting mishaps to lost reading glasses, the impact of age-related blurry near vision, or difficulty seeing things up close, on daily life can be pervasive. People who struggle with this may have presbyopia, which affects most adults over 40...(PR Newswire)

September 23, 2021
AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress

AbbVie (NYSE: ABBV) today announced it will present 27 abstracts across its dermatology portfolio, including new analyses evaluating the safety and efficacy of RINVOQ(R) (upadacitinib) in atopic dermatitis and new data on SKYRIZI(R) (risankizumab)...(PR Newswire)

September 20, 2021
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI(R)) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an...(PR Newswire)

September 16, 2021
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ(R)) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely active ulcerative...(PR Newswire)

September 10, 2021
AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. The cash dividend is payable November 15, 2021 to stockholders of record at the close of business on October 15, 2021. (PR Newswire)

AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts...(PR Newswire)

September 09, 2021
AbbVie to Present at the Morgan Stanley Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard A. Gonzalez, chairman and chief executive officer, Michael Severino, M.D., vice chairman and...(PR Newswire)

Clinical Trial of Investigational Epcoritamab (DuoBody(R)-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE(TM) NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating...(PR Newswire)

Clinical Trial of Investigational Epcoritamab (DuoBody(R)-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE(TM) NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating...(BusinessWire)

September 08, 2021
AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from...(PR Newswire)

August 24, 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ(R) (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and...(PR Newswire)

August 19, 2021
Pruritus Therapeutics Market | Analyzing Growth Opportunities in Pharmaceutical Industry | Technavio

https://mma.prnewswire.com/media/1596472/Technavio___Forecast_and_Analysis_2021_2025.jpg Technavio has been monitoring the pruritus therapeutics market and it is poised to grow by USD 4.01 billion during 2021-2025, progressing at a CAGR of almost 6%...(PR Newswire)

August 18, 2021
New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine

AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine (NEJM) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic...(PR Newswire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.